Anavex Receives FDA Clearance for Blarcamesine Fragile X Study
Anavex said its IND application for blarcamesine in Fragile X syndrome has received FDA clearance. A Phase 2a study will evaluate safety, tolerability and pharmacokinetics in adult males.
Story updates
08:01:48 PM UTC
SquawkNews
Anavex received FDA clearance to proceed with its IND for blarcamesine in Fragile X syndrome, enabling a planned Phase 2a, placebo-controlled study in ~60 adult males in the U.S.Material DetailsContext by AI AnalystThis is an early-stage regulatory milestone expanding Anavex’s clinical footprint in…